Sign Up
OverviewAPI
Johnson & Johnson (JNJ) is expected to report its Q4 fiscal 2023 earnings, with a consensus estimate of $1.10 per share. The company's stock has underperformed the S&P 500 in 2022 and 2023. However, JNJ's Q3 2023 revenues were up 8% and adjusted earnings per share improved by 160 bps. The company's Q3 2023 sales of $2.86 billion in the arthritis drug Stelara beat estimates. JNJ has also raised its 2023 profit forecast, with a focus on strong demand for Stelara.

Ask a question